TITLE: Fingolimod versus Glatiramer for Adults with Relapsing Remitting Multiple Sclerosis: Clinical and Cost-Effectiveness

DATE: 25 June 2012

RESEARCH QUESTIONS

1. What is the comparative clinical effectiveness of fingolimod and glatiramer for the treatment of relapsing remitting multiple sclerosis in adults?

2. What is the cost-effectiveness of fingolimod versus glatiramer for the treatment of relapsing remitting multiple sclerosis in adults?

KEY MESSAGE

Two meta-analyses were identified regarding the comparative clinical effectiveness and one economic evaluation was identified pertaining to the cost-effectiveness of fingolimod versus glatiramer for the treatment of relapsing remitting multiple sclerosis in adults.

METHODS

A limited literature search was conducted on key resources including PubMed, Embase, The Cochrane Library (2012, Issue 6), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No filters were applied to limit the retrieval by study type. The search was limited to English language documents published between January 1, 2007 and June 20, 2012. Internet links were provided, where available.

RESULTS

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials and economic evaluations.
Two meta-analyses were identified regarding the comparative clinical effectiveness of fingolimod and glatiramer for the treatment of relapsing remitting multiple sclerosis in adults. One economic evaluation was identified pertaining to the cost-effectiveness of fingolimod versus glatiramer for the treatment of relapsing remitting multiple sclerosis in adults. No relevant health technology assessments or randomized controlled trials were identified. Additional references of potential interest are provided in the appendix.

**Health Technology Assessments**
No literature identified.

**Systematic Reviews and Meta-analyses**


**Randomized Controlled Trials**
No literature identified.

**Economic Evaluations**

APPENDIX – FURTHER INFORMATION:

Conference Abstracts


Previous CADTH Publications